Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021
August 20, 2021 08:30 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET
August 16, 2021 16:15 ET
|
Brooklyn Immunotherapeutics LLC
BROOKLYN, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results
August 16, 2021 07:00 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that gene editing/cell and...
Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021
August 13, 2021 14:22 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn Immuno Reports Inducement Grants
July 23, 2021 16:30 ET
|
Brooklyn Immunotherapeutics LLC
BROOKLYN, N.Y., July 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
July 19, 2021 08:00 ET
|
Brooklyn Immunotherapeutics LLC
Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy Company to hold Conference Call Today, July 19, 2021, at 4:15PM ET to Discuss the...
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer
July 13, 2021 08:15 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021
July 12, 2021 08:15 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that...
Brooklyn ImmunoTherapeutics Reports Inducement Grants
July 06, 2021 17:57 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that...
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics
June 14, 2021 07:30 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene...